General Drug Use Surveillance (All-Patient Surveillance) of POLIVY for Intravenous Infusion 30mg and 140mg (polatuzumab vadotin [genetical recombination]) -Relapsed or refractory diffuse large B-cell lymphoma
Not Applicable
- Conditions
- Relapsed or refractory diffuse large B-cell lymphoma
- Registration Number
- JPRN-UMIN000043840
- Lead Sponsor
- Chugai Pharmaceutical Co. Ltd.
- Brief Summary
The incidence rate of ADRs [95% confidence interval (CI)] in the safety analysis set (1827 patients) was 49.15% (46.83 -51.47 patients) (898 patients), and 2217 ADRs occurred.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 1877
Inclusion Criteria
Not provided
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method